文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

免疫缺陷相关疫苗衍生脊髓灰质炎病毒感染病理生理学新见解:逾50年数据的系统综述

New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data.
PubMed 文献 · Vaccine · 2018-02-23

该系统综述检索Embase、Medline等数据库至2016年9月30日,纳入68篇文献共107例免疫缺陷相关疫苗衍生脊髓灰质炎病毒(iVDPV)病例,其中74例(69.81%)发生疫苗相关麻痹型脊髓灰质炎(VAPP)。联合免疫缺陷患者VAPP发生率(p < .001)和感染清除率(p = .02)均低于体液免疫缺陷患者,基因组进化速率在复制早期较高并随时间下降至稳态。

要点

  • 107例iVDPV病例中74例(69.81%)发生VAPP,多数来自高收入且脊髓灰质炎免疫覆盖高的国家。
  • 联合免疫缺陷患者VAPP发生率(p < .001)和感染清除率(p = .02)均低于体液免疫缺陷患者。
  • 基因组分化程度(p = .04)和速率(p = .03)越高,病毒清除可能性越低,独立于复制持续时间。

核心结论

  • 使用口服脊髓灰质炎疫苗(OPV)时,新的iVDPV将出现,且与免疫覆盖率无关。
  • 原发性免疫缺陷(PID)的固有特征影响iVDPV感染的临床病程和病毒进化。
  • 该发现对公共卫生、脊髓灰质炎根除工作和有效抗病毒干预措施的开发具有意义。

研究设计与样本

  • 系统综述,检索Embase、Medline、Science direct、Scopus、Web of Science及CDC和WHO数据库至2016年9月30日,纳入68篇合格文献共107例iVDPV病例。
  • 从合格研究中提取患者层面数据,从WHO/UNICEF和WORLD BANK数据库分别提取国家免疫覆盖率和收入水平数据。
  • 评估免疫学、临床和病毒学参数间的双变量关联,并用多变量建模识别脊髓灰质炎病毒进化和患者结局的独立决定因素;研究方案注册于PROSPERO(CRD42016052931)。
  • 共筛选4329条去重标题。

主要发现

  • 107例iVDPV病例中74例(69.81%)发生VAPP,多数病例来自高收入且脊髓灰质炎免疫覆盖高的国家。
  • 联合免疫缺陷患者VAPP发生率低于体液免疫缺陷患者(p < .001),感染清除率也低于体液免疫缺陷患者(p = .02)。
  • 脊髓灰质炎病毒基因组进化速率在复制早期较高,随时间下降直至达到稳态。
  • 独立于复制持续时间,基因组分化程度较高(p = .04)和速率较高(p = .03)均导致病毒清除可能性降低。
  • PID类型(p < .001)、VAPP发生(p = .008)和国家收入水平(p = .04)独立影响患者生存。

关键数值与推荐

  • 共纳入68篇合格文献,识别107例iVDPV病例。
  • 74例(69.81%)患者发生VAPP。
  • 联合免疫缺陷患者VAPP发生率低于体液免疫缺陷患者(p < .001),感染清除率低于体液免疫缺陷患者(p = .02)。
  • 基因组分化程度较高与病毒清除可能性降低相关(p = .04),基因组分化速率较高与病毒清除可能性降低相关(p = .03)。
  • PID类型(p < .001)、VAPP发生(p = .008)和国家收入水平(p = .04)独立影响患者生存。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Widespread administration of oral poliovirus vaccine (OPV) has decreased global incidence of poliomyelitis by ≈99.9%. However, the emergence of vaccine-derived polioviruses (VDPVs) is threatening polio-eradication program. Primary immunodeficiency (PID) patients are at higher risks of vaccine-associated paralytic poliomyelitis (VAPP) and prolonged excretion of immunodeficiency-associated VDPV (iVDPV). We searched Embase, Medline, Science direct, Scopus, Web of Science, and CDC and WHO databases by 30 September 2016, for all reports of iVDPV cases. Patient-level data were extracted form eligible studies. Data on immunization coverage and income-level of countries were extracted from WHO/UNICEF and the WORLD BANK databases, respectively. We assessed bivariate associations between immunological, clinical, and virological parameters, and exploited multivariable modeling to identify independent determinants of poliovirus evolution and patients' outcomes. Study protocol was registered with PROSPERO (CRD42016052931). 4329 duplicate-removed titles were screened. A total of 107 iVDPV cases were identified from 68 eligible articles. The majority of cases were from higher income countries with high polio-immunization coverage. 74 (69.81%) patients developed VAPP. Combined immunodeficiency patients showed lower rates of VAPP (p < .001) and infection clearance (p = .02), compared to humoral immunodeficiency patients. The rate of poliovirus genomic evolution was higher at early stages of replication, decreasing over time until reaching a steady state. Independent of replication duration, higher extent (p = .04) and rates (p = .03) of genome divergence contributed to a less likelihood of virus clearance. PID type (p < .001), VAPP occurrence (p = .008), and income-level of country (p = .04) independently influenced patients' survival. With the use of OPV, new iVDPVs will emerge independent of the rate of immunization coverage. Inherent features of PIDs contribute to the clinical course of iVDPV infection and virus evolution. This finding could shed further light on poliomyelitis pathogenesis and iVDPV evolution pattern. It also has implications for public health, the polio eradication effort and the development of effective antiviral interventions.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shaghaghi M, Soleyman-Jahi S, Abolhassani H, et al. New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data. Vaccine. 2018. PMID: 29478755. doi:10.1016/j.vaccine.2018.02.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。